

Optum clinicogenomics: Powering next-generation health care



Life sciences organizations need commercially available clinicogenomics data to drive novel discovery. Its insights will play a pivotal role in fueling next-generation novel drug discovery, development and commercialization. At Optum, we define clinicogenomics as a data set comprised of both genomic and phenotypic data.

However, such data-driven innovation is not without its challenges. Recruitment efforts are broad and do not target areas of high unmet need. Acquiring genomic data resources is time intensive and cost prohibitive, given typically inconsistent data quality and depth, with limited access to linked clinical data.

Optum clinicogenomics solves these challenges with a strong foundation of:



**Access to large-scale,
diverse real-world
patient cohorts at scale**



**Linking high-quality
genomic data and
rich, longitudinal
phenotype data**



**Domain expertise in
clinicogenomics and
technology**

Optum clinicogenomics:
Powering next-generation health care

Innovate from discovery through commercialization

Our access to millions of patients and our vision to link the exome sequence to rich claims and electronic health record data from across the health care ecosystem gives us deep insights into mechanisms of disease and treatment response. This uniquely positions us to provide the required scale and consistency necessary to achieve better, faster and less expensive drug development.

- **Patient access:** Target highly characterized cohorts and support your pipeline-specific recruitment needs through access to large-scale, diverse patient populations. This helps achieve research recruitment goals, improve the patient experience and increase population health safety.
- **Genomic data:** Ignite discovery with confidence using consistently high-quality whole exome sequence (WES) and whole genome sequence (WGS) data.
- **Linking phenotype data:** Accelerate time to market through robust linked genomic and phenotypic data that provide a complete picture of the patient and improve regulatory approval success rate.
- **Domain expertise:** Mitigate the risk of conducting research and increase scale by leveraging our robust analytics and team of genomic and technology experts. Our secure data storage architecture keeps data protected.

Fuel your next discovery

Optum clinicogenomics expands our data-driven insights and streamlines the process of drug research and development. This translates to fewer resources and less time allocated to patient recruitment, data storage, unsuccessful research and development, and time to market. Partner with Optum clinicogenomics to:

- Discover high-value biomarkers for drug development
- Decrease time to market
- Improve regulatory approval success rate
- Streamline research recruitment and development process



11000 Optum Circle, Eden Prairie, MN 55344

Optum® is a registered trademark of Optum, Inc. in the U.S. and other jurisdictions. All other brand or product names are the property of their respective owners. Because we are continuously improving our products and services, Optum reserves the right to change specifications without prior notice. Optum is an equal opportunity employer.

© 2021 Optum, Inc. All rights reserved. WF3962710 03/21

To learn how Optum clinicogenomics can help fuel your next discovery, please contact us.

Visit: optum.com/clinicogenomics
